Previous 10 | Next 10 |
PHILADELPHIA, Sept. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today presented updated clinical and translational data thro...
The shares of Cabaletta Bio ( NASDAQ: CABA ), a biotech focused on T cell therapies, fell ~5% in the pre-market trading Monday after Morgan Stanley downgraded the company to Equal Weight, citing an upcoming data readout for its lead asset DSG3-CAART. On Monday, CABA anno...
Penny stocks typically trade for less than $5 per share and tend to be highly volatile. But this wild price action has attracted so many retail traders over time. Whether we’re talking about OTC penny stocks or ones trading on the NYSE or NASDAQ, there are hundreds to choose from...
Cabaletta Bio press release ( NASDAQ: CABA ): Q2 GAAP EPS of -$0.45 beats by $0.05 . As of June 30, 2022, the Company had cash and cash equivalents of approximately $29.8 million, compared with approximately $52.9 million as of September 30, 2021. For further det...
PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today reported financial results for the second quarter ended...
Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...
Clinical-stage biotech, Cabaletta Bio (NASDAQ:CABA) announced additional interim data for its lead candidate DSG3-CAART from a Phase 1 trial called DesCAARTes in adults with mucosal-dominant pemphigus vulgaris (mPV), a rare skin disorder. The open label study was designed to identify the maxi...
PHILADELPHIA, May 18, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today presented updated clinical and translational data throug...
PHILADELPHIA, May 17, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., President and C...
Cabaletta Bio press release (NASDAQ:CABA): Q1 GAAP EPS of -$0.45. As of March 31, 2022, Cabaletta had cash, cash equivalents and investments of $109.2 million, compared to $122.2 million as of December 31, 2021. For further details see: Cabaletta Bio GAAP EPS of -$0.45
News, Short Squeeze, Breakout and More Instantly...
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtb...
2024-06-20 09:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both...